FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2918183744> ?p ?o ?g. }

• W2918183744 abstract "ctDNA analysis offers a non-invasive approach for monitoring response and resistance to treatment. Serial ctDNA testing during neoadjuvant therapy (NAT) may provide early indicators of emerging resistance and disease progression. In this study, we analyzed ctDNA from high-risk early breast cancer patients who received NAT and definitive surgery in the I-SPY 2 TRIAL (NCT01042379). We hypothesize that (1) assessment of ctDNA levels early in treatment will improve the performance of molecular and imaging-based predictors of pathologic complete response (pCR) to NAT; and (2) levels of ctDNA after NAT are associated with residual cancer burden and recurrence [distant recurrence free survival (DRFS)]. Methods: ctDNA analysis was performed in 84 high-risk stage II and III breast cancer patients randomized to neoadjuvant investigational agent (n=52), AKT inhibitor MK-2206 (M) in combination with paclitaxel (T) followed by doxorubicin and cyclophosphamide (AC) (M+T->AC), or standard-of-care (T->AC) (n=32). HER2+ patients also received trastuzumab (H). Serial plasma was collected before NAT (T0), early treatment (3 weeks, T1), between regimens (12 weeks, T2), and after NAT prior to surgery (T3). Mutational profiles derived from pretreatment tumor biopsy and normal matched DNA whole exome sequencing were used to design personalized assays targeting 16 patient-specific somatic variants to detect ctDNA in serial plasma. Results: Of the 84 patients in this study, 43% were HR-/HER2- (TNBC), 35% HR+/HER2-, and 23% HER2+. In total, 74% (61 of 83), 35% (28 of 79), 14% (9 of 65), and 8% (5 of 61) were positive for ctDNA at timepoints T0, T1, T2, and T3, respectively. At T0, ctDNA positivity and levels (average number of mutant molecules detected per mL) were significantly associated with increased tumor burden (by clinical and MRI examination), more aggressive tumor biology (as reflected in higher Mammaprint scores and grade) and subtype (HER2+ and TNBC). Twenty-seven percent (27%) of the 84 patients achieved a pCR and all patients who were ctDNA-positive at T3 (n=5) did not achieve a pCR. Currently, data are being collected to: (1) assess the relationship of ctDNA and MRI imaging in predicting tumor response to therapy; (2) examine the relationship of ctDNA levels before and after NAT with 3-year DRFS and event-free survival (EFS). The results of these analyses will be presented at the SABCS 2018 meeting. Conclusions: Our study provides a platform to evaluate the clinical significance of ctDNA for serial monitoring of response to NAT. Accurate and early response prediction by highly sensitive ctDNA analysis can facilitate a timely and judicious change in treatment to improve patients9 chances of achieving a pCR. Finally, personalized ctDNA testing may complement imaging and pathologic evaluation of tumor response to fine-tune pCR as a surrogate endpoint for improved DRFS and EFS. Citation Format: Magbanua MJM, Brown-Swigart L, Hirst GL, Yau C, Wolf D, Ma AA, Bergin E, Venters S, Sethi H, Wu H-T, Salari R, Tin T, Sawyer S, Louie M, Zimmermann B, Lin C-HJ, Keats J, Liang WS, Cuyugan L, Enriquez D, Tripathy D, Chien AJ, Forero A, DeMichele A, Liu M, Delson AL, Asare S, Esserman L, van9t Veer L, I-SPY 2 Consortium. Personalized serial circulating tumor DNA (ctDNA) analysis in high-risk early stage breast cancer patients to monitor and predict response to neoadjuvant therapy and outcome in the I-SPY 2 TRIAL [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr PD2-01." @default.
• W2918183744 created "2019-03-11" @default.
• W2918183744 creator A5003164005 @default.
• W2918183744 creator A5003953329 @default.
• W2918183744 creator A5004885263 @default.
• W2918183744 creator A5005226326 @default.
• W2918183744 creator A5005537242 @default.
• W2918183744 creator A5008702162 @default.
• W2918183744 creator A5014225184 @default.
• W2918183744 creator A5016497396 @default.
• W2918183744 creator A5018310163 @default.
• W2918183744 creator A5022349536 @default.
• W2918183744 creator A5023674071 @default.
• W2918183744 creator A5043643636 @default.
• W2918183744 creator A5043719516 @default.
• W2918183744 creator A5044918813 @default.
• W2918183744 creator A5045249036 @default.
• W2918183744 creator A5046549002 @default.
• W2918183744 creator A5052816330 @default.
• W2918183744 creator A5059305173 @default.
• W2918183744 creator A5062190609 @default.
• W2918183744 creator A5065344327 @default.
• W2918183744 creator A5065711396 @default.
• W2918183744 creator A5066744904 @default.
• W2918183744 creator A5080636347 @default.
• W2918183744 creator A5084723808 @default.
• W2918183744 creator A5085500713 @default.
• W2918183744 creator A5085850492 @default.
• W2918183744 creator A5087168847 @default.
• W2918183744 creator A5088644696 @default.
• W2918183744 creator A5090425501 @default.
• W2918183744 date "2019-02-15" @default.
• W2918183744 modified "2023-10-17" @default.
• W2918183744 title "Abstract PD2-01: Personalized serial circulating tumor DNA (ctDNA) analysis in high-risk early stage breast cancer patients to monitor and predict response to neoadjuvant therapy and outcome in the I-SPY 2 TRIAL" @default.
• W2918183744 doi "https://doi.org/10.1158/1538-7445.sabcs18-pd2-01" @default.
• W2918183744 hasPublicationYear "2019" @default.
• W2918183744 type Work @default.
• W2918183744 sameAs 2918183744 @default.
• W2918183744 citedByCount "4" @default.
• W2918183744 countsByYear W29181837442019 @default.
• W2918183744 countsByYear W29181837442021 @default.
• W2918183744 crossrefType "proceedings-article" @default.
• W2918183744 hasAuthorship W2918183744A5003164005 @default.
• W2918183744 hasAuthorship W2918183744A5003953329 @default.
• W2918183744 hasAuthorship W2918183744A5004885263 @default.
• W2918183744 hasAuthorship W2918183744A5005226326 @default.
• W2918183744 hasAuthorship W2918183744A5005537242 @default.
• W2918183744 hasAuthorship W2918183744A5008702162 @default.
• W2918183744 hasAuthorship W2918183744A5014225184 @default.
• W2918183744 hasAuthorship W2918183744A5016497396 @default.
• W2918183744 hasAuthorship W2918183744A5018310163 @default.
• W2918183744 hasAuthorship W2918183744A5022349536 @default.
• W2918183744 hasAuthorship W2918183744A5023674071 @default.
• W2918183744 hasAuthorship W2918183744A5043643636 @default.
• W2918183744 hasAuthorship W2918183744A5043719516 @default.
• W2918183744 hasAuthorship W2918183744A5044918813 @default.
• W2918183744 hasAuthorship W2918183744A5045249036 @default.
• W2918183744 hasAuthorship W2918183744A5046549002 @default.
• W2918183744 hasAuthorship W2918183744A5052816330 @default.
• W2918183744 hasAuthorship W2918183744A5059305173 @default.
• W2918183744 hasAuthorship W2918183744A5062190609 @default.
• W2918183744 hasAuthorship W2918183744A5065344327 @default.
• W2918183744 hasAuthorship W2918183744A5065711396 @default.
• W2918183744 hasAuthorship W2918183744A5066744904 @default.
• W2918183744 hasAuthorship W2918183744A5080636347 @default.
• W2918183744 hasAuthorship W2918183744A5084723808 @default.
• W2918183744 hasAuthorship W2918183744A5085500713 @default.
• W2918183744 hasAuthorship W2918183744A5085850492 @default.
• W2918183744 hasAuthorship W2918183744A5087168847 @default.
• W2918183744 hasAuthorship W2918183744A5088644696 @default.
• W2918183744 hasAuthorship W2918183744A5090425501 @default.
• W2918183744 hasConcept C121608353 @default.
• W2918183744 hasConcept C126322002 @default.
• W2918183744 hasConcept C143998085 @default.
• W2918183744 hasConcept C146357865 @default.
• W2918183744 hasConcept C151730666 @default.
• W2918183744 hasConcept C2776694085 @default.
• W2918183744 hasConcept C2776755627 @default.
• W2918183744 hasConcept C2778292576 @default.
• W2918183744 hasConcept C2779529041 @default.
• W2918183744 hasConcept C2779786085 @default.
• W2918183744 hasConcept C2781335228 @default.
• W2918183744 hasConcept C530470458 @default.
• W2918183744 hasConcept C71924100 @default.
• W2918183744 hasConcept C86803240 @default.
• W2918183744 hasConceptScore W2918183744C121608353 @default.
• W2918183744 hasConceptScore W2918183744C126322002 @default.
• W2918183744 hasConceptScore W2918183744C143998085 @default.
• W2918183744 hasConceptScore W2918183744C146357865 @default.
• W2918183744 hasConceptScore W2918183744C151730666 @default.
• W2918183744 hasConceptScore W2918183744C2776694085 @default.
• W2918183744 hasConceptScore W2918183744C2776755627 @default.
• W2918183744 hasConceptScore W2918183744C2778292576 @default.
• W2918183744 hasConceptScore W2918183744C2779529041 @default.
• W2918183744 hasConceptScore W2918183744C2779786085 @default.
• W2918183744 hasConceptScore W2918183744C2781335228 @default.
• W2918183744 hasConceptScore W2918183744C530470458 @default.
• W2918183744 hasConceptScore W2918183744C71924100 @default.
• W2918183744 hasConceptScore W2918183744C86803240 @default.
• W2918183744 hasLocation W29181837441 @default.

• next